Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck

« Previous Next »International Journal of Radiation Oncology * Biology * Physics
Volume 51, Issue 3 , Pages 599-604, 1 November 2001

A.Dimitrios Colevas, M.D.
- Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston MA, USA
- Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- Reprint requests to: A. Dimitrios Colevas, M.D., Investigational Drug Branch, Cancer Therapy Evaluation Program, DCTD, National Cancer Institute, Executive Plaza North, Room 7131, 6130 Executive Blvd., Rockville, MD 20852-7426. Tel: 301 435-9128; Fax: 301 402 0428
Richard Read, B.A.
- Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston MA, USA
John Thornhill, B.A.
- Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston MA, USA
Sudeshna Adak, Ph.D.
- Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA
Roy Tishler, M.D., Ph.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
Paul Busse, M.D.
- Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA
Yi Li, Ph.D.
- Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA, USA
Marshall Posner, M.D.
- Head and Neck Oncology Program, Dana-Farber Cancer Institute, Boston MA, USA
- Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA